un medicated diagnosed with major depression and scheduled to start SSRI treatment.

Depression

no intervention is being performed, only observational evaluations.

no intervantion

PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility

david groshar

Assuta Medical Center

Cancer Cachexia

Ruxolitinib

Division of Hematology/Oncolgy, University Clinic of Medicine, Kantonsspital Aarau AG

Division of Hematology/Oncology, Kantonsspital Olten

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

Dual energy X-ray absorptiometry (DEXA) and bioelectrical impedance analysis (BIA)

Formula BMI = W / H2 (W=body weight in kilograms; H=body height in meters)

Reporting of adverse events according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Measurement of power and speed on a stair climbing test (Stair climb speed [m/sec]=[height of 12 steps(meters)]/[time (seconds) up the 12 steps]; Stair climb power [watts]=[9.8 m/sec2]*[weight (kg)]*[height of 12 steps(meters)]/[time (seconds) up the 12 steps]).

Multiplex-assays for proinflammatory cytokines

Free oxygen radical monitor (FORM) with proper kits (FORMOX with FORT and FORD analysis kits, Callegari 1930 S.P.A., Parma, Italy).

proteinase/hâlsizlik

PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı